

In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

1. Identification of the substance or preparation and the company/ undertaking				
1.1 Product Identifier				
Product Name: MASTRING <sup>™</sup> MID	8			
Product Code: MID8				
1.2 Relevant identified uses of the substance or mixture and uses advised against				
Recommended uses: In vitro diagnostic	product; Laboratory chemical			
Uses advised against: No information av	No information available			
1.3 Details of supplier of the product and safety data sheet				
Manufacturer/supplier:Mast Group Ltd., Mast House, Derby Road, Bootle, Merseyside, UK. L20 1EA Telephone: +44 (0) 151 933 7277 Email: uksales@mastgrp.com Web: www.mast-group.comFeldstraße 20 23858 Reinfeld Germany Telephone: +49 4533 20 07 34 Email: mast@mast-diagnostica.de Web: www.mast-group.com				
<b>1.4</b> <u>Emergency Contact information</u> UK contact: Telephone: +44 (0) 151 933 7277 (8am - 5pm GMT Monday to Friday) EU contact: Telephone: +49 4533 20 07 34 (7am - 4pm GMT Monday to Friday)				
	2. Hazards identification			
2.1 <u>Classification of the substance or mixture</u>				
CLP Classification – Regulation (EC) No. 1272/2008				
Physical hazards				
Heath hazards				
Environmental hazards	Based on available data, there are no environmental hazards			
2.2 Label elements				
Pictogram				
Signal word				
Hazard statements				
Precautionary statements	: None			
2.3 <u>Other hazards</u>	No information available			



### In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

#### 3. Composition/information on ingredients

**Composition:** A paper ring containing erythromycin, rifampicin, colistin sulphate, penicillin G, kanamycin and Vancomycin in buffered bases. All components present in small quantities i.e. <1mg per disc.

#### Hazardous ingredients:

Component	CAS-No.	EC-No.	Concentration	CLP Classification – 1272/2008/EC
Rifampicin	13292-46-1	236-312-0	15µg/disc	Acute toxicity, Oral (Category 4), H302
				Skin irritation (Category 2), H315
				Eye irritation (Category 2), H319
				Specific target organ toxicity - single exposure (Category 3), Respiratory
				system, H335
Colistin sulphate	1264-72-8	215-034-3	10µg/disc	Acute toxicity, Oral (Category 3),
				H301 – Toxic if swallowed
Penicillin G sodium	69-57-8	200-710-2	2 unit/disc	Respiratory sensitization (Category 1)
				Skin sensitization (Category 1)
				H317 - May cause an allergic skin reaction.
				H334 - May cause allergy or asthma symptoms or breathing difficulties if
				inhaled.
Kanamycin	25389-94-9	246-933-9	1000µg/disc	Reproductive toxicity (Category 1B)
sulphate				H360 - May damage fertility or the unborn child.
Vancomycin HCI	1404-93-9		5µg/disc	Skin sensitisation (Category 1),
			5F.9/ 0100	H317 – may cause an allergic skin reaction.

### 4. First-aid measures

#### 4.1 Description of First Aid measures

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance.

Eye contact: Rinse thoroughly with plenty of water for 10 to 15 minutes, also under the eyelids. Obtain medical attention if irritation persists.

Skin Contact: Wash off skin thoroughly with soap and plenty of water. Obtain medical attention if irritation persists.

Ingestion: Rinse mouth out with plenty of water. Obtain medical attention if symptoms occur.

Inhalation: Move person to fresh air. Obtain medical attention immediately if symptoms occur.

#### 4.2 Most important symptoms and effects, both acute and delayed

No information available.

#### 4.3 Indicate any immediate medical attention and special treatment needed

No information available.

#### 5. Fire fighting measures

#### 5.1 Extinguishing medium

Suitable extinguishing media: Use water spray, CO<sub>2</sub>, foam or dry powder as the extinguisher medium.

Extinguishing media which must not be used for safety reasons: No information available

## 5.2 Special hazards arising from the substance or mixture

Combustible material. Thermal decomposition may lead to release of irritating gases and vapours.

#### 5.3 Advice for firefighters

Wear suitable self contained breathing apparatus for fire fighting if necessary.



In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

#### 5.4 Additional information

#### No data available.

#### 6. Accidental release measures

#### 6.1 <u>Personal precautions, protective equipment and emergency procedures</u>

Ensure adequate ventilation. Wear appropriate protective equipment. Avoid dust formation.

#### 6.2 Environmental precautions

Should not be released into the environment.

#### 6.3 Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage in suitable container for disposal. Avoid dust formation.

### 6.4 Further information

No data available.

#### 7. Handling and storage

#### 7.1 Precautions for safe handing

Avoid contact with eyes, skin and clothing. Avoid ingestion and inhalation. Avoid dust formation. Use forceps when handling product.

#### 7.2 Conditions for safe storage, including any incompatabilities

Store at 2°C to 8°C. Keep tightly closed in the container provided. Protect from direct sunlight and moisture.

#### 7.3 Specific end use(s)

This product is for laboratory use only and should only be used by suitably trained laboratory personnel.

#### 8. Exposure controls and personal protection

#### 8.1 Control parameters

Components with workspace control parameters: Contains no substance with occupational exposure limits.

#### 8.2 Exposure controls

Engineering controls:	No engineering protection required.		
Personal protective measures:	Body protection:	Wear standard microbiology laboratory coat.	
	Eye/face protection:	Safety glasses with side shields conforming to EN 166.	
	Skin and hand protection:	Handle with suitable gloves conforming to EN 374. Product may be handled with forceps.	
	Respiratory protection:	If required use a nuisance type particle respirator type P1 EU EN 143.	
General hygiene measures:	Handle in accordance with good laboratory practice. Wash hands before breaks and at the end of the working day.		



In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

## 9. Physical and Chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state:	A filter paper ring with 6 arms each leading to a 6mm paper discs.
Colour:	White or coloured discs.
Odour:	Odourless.
Melting point/freezing point:	No data available.
Initial boiling point/range:	No data available.
Flammability:	No data available.
Lower and upper explosion limit:	No data available.
Flash point:	No data available.
Auto-ignition temperature:	No data available.
Decomposition temperature:	No data available.
pH	No data available.
Kinetic viscosity:	No data available.
Solubility in water/other solvents:	No data available.
Partition coefficient (n-octanol/water):	No data available.
Vapour pressure:	No data available.
Density/Relative density:	No data available.
Relative vapour density:	No data available.
Decomposition temperature	No data available.
Particle characteristics:	No data available.

#### 9.2 Other information

No data available.

## 10. Stability and reactivity

10.1 Reactivity

None known on information available.

#### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

No data available.

## 10.4 Conditions to avoid

Incompatible products; Avoid heat; Avoid dust formation.

#### 10.5 Incompatible materials

None known.

## 10.6 Hazardous decomposition products

None under normal use conditions.



In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

11. Toxicological information				
11.1 Information on toxicological effects				
Overall product information: This product does not present an acute toxicity based on known or supplied information.				
Acute toxicity:	Rifampicin: LD50 Oral - rat - 1,570 mg/kg Colistin sulphate: LD50 Oral - rat - 121 mg/kg Penicillin G: LD50 Oral - rat - 6,916 mg/kg Kanamycin: LD50 Oral - rat - > 4,000 mg/kg, LD50 Intravenous - rat - 225 mg/kg, LD50 Intramuscular - rat - > 4,000 mg/kg, LD50 Subcutaneous - rabbit - > 3 g/kg, LD50 Intravenous - rabbit - 550 mg/kg, LD50 Intramuscular - rabbit - > 3 g/kg, LD50 Intraperitoneal - mouse - 1,353 mg/kg, LD50 Subcutaneous - mouse - 1,100 mg/kg. Vancomycin: LD50 Oral - rat - > 10,000 mg/kg			
Skin corrosion/irritation:	No data available.			
Serious eye damage/ eye irritation:	No data available.			
Respiratory or skin sensitisation:	No data available.			
Germ cell mutagenicity:	No data available.			
Carcinogenicity:	IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (Rifampicin)			
Reproductive toxicity:	<ul> <li>Kanamycin: Reproductive toxicity - rat - female – Intramuscular; Maternal Effects: Other effects.</li> <li>Specific Developmental Abnormalities: Urogenital system.</li> <li>Reproductive toxicity - rat - female - Subcutaneous Effects on Embryo or Fetus: Foetal death. Specific Developmental</li> <li>Abnormalities: Musculoskeletal system.</li> <li>Reproductive toxicity - guinea pig - female - Intramuscular Specific Developmental Abnormalities: Eye, ear.</li> <li>Presumed human reproductive toxicant</li> </ul>			
Specific target organ toxicity – single exposure:	No data available.			
Specific target organ toxicity – repeated exposure:	No data available.			
Aspiration hazard:	No data available.			
Potential health effects:	Inhalation - May be harmful if inhaled. May cause respiratory tract irritation. Ingestion - May be harmful if swallowed. Skin - May be harmful if absorbed through skin. May cause skin irritation. Eyes - May cause eye irritation.			
	To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.			
	RTECS: Rifampicin - VJ7000000. RTECS: Colistin sulphate - TR1500000. Prolonged or repeated exposure can cause: neurotoxic effects; liver injury may occur; anorexia; headache; vomiting; diarrhoea; nausea; ataxia. RTECS: Penicillin G - XH9800000 RTECS: Kanamycin - NZ3225030 RTECS: Vancomycin - YW4380000			

## 11.2 Information on other hazards

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.



#### In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

### 12. Ecological information

#### 12.1 Toxicity

This product is not known to be hazardous to the environment or not degradable in waste water treatment plants.

#### 12.2 Persistence and degradability

Expected to be biodegradable.

#### 12.3 Bioaccumulative potential

No data available.

### 12.4 Mobility in soil

No data available.

#### 12.5 Results of PBT and vPvB assessment

None known.

## 12.6 Endocrine disrupting properties: requiring you to give product information on adverse effects on the environment caused by endocrine-disrupting properties

12.7 Other adverse effects.

This product does not contain any known or suspected endocrine disruptors.

#### 2.1 Other adverse effects.

No data available.

## 13. Disposal considerations

Disposal considerations: Dispose of in accordance with local and national regulations. Dispose of contaminated waste, e.g. used plates, according to local microbiological rules.

### 14. Transport information

### 14.1 <u>UN Number</u>

ADR/RID: IMDG: IATA: Not dangerous for shipping

## 14.2 UN proper shipping name

ADR/RID: IMDG: IATA: Not dangerous for shipping

## 14.3 Transport hazard class(es)

ADR/RID: IMDG: IATA: Not dangerous for shipping

#### 14.4 Packaging group

ADR/RID: IMDG: IATA: Not dangerous for shipping

#### 14.5 Environmental hazards

ADR/RID: IMDG: IATA: None known.

#### 14.6 Special precautions for user

No data available

## 14.7 Maritime transport in bulk according to IMO instruments

No data available



In accordance with Regulation (EC) No 2020/878 Revision date: 21/09/2022 Version number: 06

## 15. Regulatory information 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture No data available. 15.2 Chemical safety assessment Chemical safety assessment reports are not required for mixtures/IVD products. 16. Other information Original origination date: 02/11/1996 Updated in accordance with Regulation (EC) No 2020/878 Reason for change to document: The above information is believed to be correct but does not purport to be all inclusive and shall be used as a guide only. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product and is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. Mast Group Ltd. shall not be held liable for any damage resulting from handling or from contact with the above product. See our website

at www.mast.grp.com and/or the reverse side of our invoice for additional terms and conditions of sale.